AstraZeneca extends multi-year Oncology Data Alliance
Tempus AI and AstraZeneca have finalized a Fifth Amendment to extend their strategic oncology collaboration through the Renewal Term starting January 1, 2027. This secures continued cooperation in drug discovery, data integration, and clinical operations.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed